大学化学 >> 2022, Vol. 37 >> Issue (9): 2206066.doi: 10.3866/PKU.DXHX202206066

所属专题： 化学科普(2022)

科普 上一篇    下一篇

吉妥单抗复兴史

吴仪1, 刘睿1,*(), 吕弋2   

  1. 1 四川大学化学学院，成都 610064
    2 四川大学分析测试中心, 成都 610064
  • 收稿日期:2022-06-20 录用日期:2022-09-16 发布日期:2022-09-16
  • 通讯作者: 刘睿 E-mail:liur@scu.edu.cn
  • 作者简介:刘睿, Email: liur@scu.edu.cn
  • 基金资助:
    四川大学大学生创新训练计划项目(20220310L)

Renaissance of Gemtuzumab Ozogamicin

Yi Wu1, Rui Liu1,*(), Yi Lv2   

  1. 1 College of Chemistry, Sichuan University, Chengdu 610064, China
    2 Analytical & Testing Center, Sichuan University, Chengdu 610064, China
  • Received:2022-06-20 Accepted:2022-09-16 Published:2022-09-16
  • Contact: Rui Liu E-mail:liur@scu.edu.cn

RichHTML

35

PDF

884

赞

摘要：

采用访谈的形式，以首个上市的抗体偶联药物“吉妥单抗”的传奇历程为明线，靶向药物在化学分子设计和分析检测上的进步为暗线，讲述了抗体偶联药物的发展史。较为全面地介绍了抗体偶联药物的化学结构、设计思路、分析方法与发展前景。

关键词: 抗体偶联药物(ADC), 吉妥单抗(Mylotarg), 靶向治疗, 抗体药物比(DAR), 尺寸排阻色谱(SEC), 疏水作用色谱(HIC)

Abstract:

This study describes the history of the development of antibody-drug conjugate in the form of interviews. The recognized history of the first commercially available antibody-drug conjugate "getuzumab" was used as the open line, whereas the progress of targeted drugs in chemical molecular design and analysis and detection was used as the dark line. The chemical structure, design, analysis, and development prospects of antibody-drug conjugates were comprehensively introduced.

Key words: Antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (Mylotarg), Targeted therapy, Antibody drug ratio (DAR), Size exclusion chromatography (SEC), Hydrophobic interaction chromatography (HIC)